HC Wainwright Issues Pessimistic Estimate for HOWL Earnings

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) – HC Wainwright lowered their Q1 2025 earnings per share (EPS) estimates for Werewolf Therapeutics in a research report issued on Wednesday, March 12th. HC Wainwright analyst A. Maldonado now anticipates that the company will post earnings of ($0.43) per share for the quarter, down from their previous forecast of ($0.38). HC Wainwright has a “Buy” rating and a $15.00 price objective on the stock. The consensus estimate for Werewolf Therapeutics’ current full-year earnings is ($1.56) per share. HC Wainwright also issued estimates for Werewolf Therapeutics’ Q2 2025 earnings at ($0.45) EPS, Q3 2025 earnings at ($0.47) EPS, Q4 2025 earnings at ($0.30) EPS, FY2025 earnings at ($1.65) EPS, FY2026 earnings at ($0.81) EPS, FY2027 earnings at ($1.56) EPS, FY2028 earnings at ($1.07) EPS and FY2029 earnings at ($0.64) EPS.

HOWL has been the topic of several other research reports. Wedbush restated an “outperform” rating and issued a $8.00 price target on shares of Werewolf Therapeutics in a research note on Wednesday, March 12th. JMP Securities lowered their price objective on Werewolf Therapeutics from $12.00 to $4.00 and set a “market outperform” rating on the stock in a research report on Tuesday, January 14th.

Werewolf Therapeutics Stock Down 0.9 %

HOWL stock opened at $1.16 on Monday. Werewolf Therapeutics has a fifty-two week low of $1.03 and a fifty-two week high of $6.89. The business’s 50 day moving average price is $1.34 and its two-hundred day moving average price is $1.79. The company has a debt-to-equity ratio of 0.29, a quick ratio of 10.10 and a current ratio of 10.10. The company has a market capitalization of $52.00 million, a price-to-earnings ratio of -0.76 and a beta of 0.37.

Werewolf Therapeutics (NASDAQ:HOWL) last announced its quarterly earnings results on Tuesday, March 11th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.03). Werewolf Therapeutics had a negative net margin of 578.80% and a negative return on equity of 58.83%.

Hedge Funds Weigh In On Werewolf Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. D. E. Shaw & Co. Inc. bought a new position in shares of Werewolf Therapeutics during the 4th quarter valued at $26,000. Regal Investment Advisors LLC lifted its holdings in shares of Werewolf Therapeutics by 88.1% during the 4th quarter. Regal Investment Advisors LLC now owns 27,204 shares of the company’s stock valued at $40,000 after buying an additional 12,745 shares during the period. XTX Topco Ltd bought a new position in Werewolf Therapeutics in the 3rd quarter worth $45,000. Levin Capital Strategies L.P. bought a new position in Werewolf Therapeutics in the 4th quarter worth $74,000. Finally, Jane Street Group LLC raised its holdings in Werewolf Therapeutics by 261.2% in the 4th quarter. Jane Street Group LLC now owns 54,713 shares of the company’s stock worth $81,000 after purchasing an additional 39,564 shares during the period. 64.84% of the stock is owned by institutional investors.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.